Cephalon Reinvention Puts Biologics Front And Center
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain.